TY - JOUR
T1 - New Boron Delivery Agents
AU - Becker, Daniel P
AU - Beck-Sickinger, Annette G
AU - Becker, Daniel P.
AU - Chepurna, Oksana
AU - Flieger, Sebastian
AU - Hey-Hawkins, Evamarie
AU - Jalisatgi, Satish S
AU - Nakamura, Hiroyuki
AU - Patil, Rameshwar
AU - Vicente, Maria da Graça H.
AU - Viñas, Clara
PY - 2022
Y1 - 2022
N2 - This proceeding article compiles current research on the development of boron delivery drugs for boron neutron capture therapy that was presented and discussed at the National Cancer Institute (NCI) Workshop on Neutron Capture Therapy that took place on April 20–22, 2022. The most used boron sources are icosahedral boron clusters attached to peptides, proteins (such as albumin), porphyrin derivatives, dendrimers, polymers, and nanoparticles, or encapsulated into liposomes. These boron clusters and/or carriers can be labeled with contrast agents allowing for the use of imaging techniques, such as PET, SPECT, and fluorescence, that enable quantification of tumor-localized boron and their use as theranostic agents.
AB - This proceeding article compiles current research on the development of boron delivery drugs for boron neutron capture therapy that was presented and discussed at the National Cancer Institute (NCI) Workshop on Neutron Capture Therapy that took place on April 20–22, 2022. The most used boron sources are icosahedral boron clusters attached to peptides, proteins (such as albumin), porphyrin derivatives, dendrimers, polymers, and nanoparticles, or encapsulated into liposomes. These boron clusters and/or carriers can be labeled with contrast agents allowing for the use of imaging techniques, such as PET, SPECT, and fluorescence, that enable quantification of tumor-localized boron and their use as theranostic agents.
U2 - 10.1089/cbr.2022.0060
DO - 10.1089/cbr.2022.0060
M3 - Article
JO - Cancer Biotherapy and Radiopharmaceuticals
JF - Cancer Biotherapy and Radiopharmaceuticals
ER -